Investigational drug · Phase 3
ABC
Also called: 3TC STR, 3TC immediate release, 3TC dispersible
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for HIV Infections.
Phase 3Last checked: Nov 19, 2026Latest source record: Jul 30, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
2
1 still active
All registered trials
514
Any phase or sponsor naming "ABC"
First trial start
2016
Oct 27, 2016
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABC", any sponsor or status.
Conditions studied
As listed on its trial records.
- HIV Infections
Approved drugs for the same conditions: Infectious disease and vaccines
Largest trials
Live from ClinicalTrials.gov: studies naming "ABC" as an intervention, largest first.
National Institutes of Health Clinical Center (CC)NIH
NCT00004846 · 30,000 participants · Start Dec 1999
Drug: ABC/Gen-Probe/Chiron HIV-1/HCV 001 · For: Hepatitis C; HIV Infection
Sites: Bethesda, Maryland
- Moving on After Breast Cancer Trial for Depressed Breast Cancer Survivors in PakistanPivotal-lookingRecruiting
Pakistan Institute of Living and LearningAcademic, hospital or other
NCT07015944 · 26,376 participants (planned) · Start Jun 13, 2025 · Primary completion Dec 30, 2028
Drug: Standardised pharmacological treatment (antidepressants) · For: Major Depressive Disorder (MDD); Breast Cancer Survivor
Sites: Karachi, Pakistan
- Tamoxifen, Ovarian Ablation, and/or Chemotherapy in Treating Women With Stage I, Stage II, or Stage IIIA Breast CancerPivotal-lookingCompleted
Institute of Cancer Research, United KingdomAcademic, hospital or other
NCT00002582 · 6,000 participants (planned) · Start Jun 1993
Drug: CMF regimen; cyclophosphamide and 6 more · For: Breast Cancer
Sites: Birmingham, United Kingdom; Glasgow, United Kingdom
- I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast CancerPivotal-lookingRecruiting
QuantumLeap Healthcare CollaborativeAcademic, hospital or other
NCT01042379 · 5,000 participants (planned) · Start Mar 1, 2010 · Primary completion Dec 2030
Drug: Standard Therapy; AMG 386 with or without Trastuzumab and 44 more · For: Breast Neoplasms; Breast Cancer; Breast Tumors and 8 more
Sites: Birmingham, Alabama; Scottsdale, Arizona; Tucson, Arizona · 42 sites in all
- Study to Assess the Safety and Efficacy of Ribociclib (LEE011) in Combination With Letrozole for the Treatment of Men and Pre/Postmenopausal Women With HR+ HER2- aBCPivotal-lookingCompleted
Novartis PharmaceuticalsNovartis (NVS)
NCT02941926 · 3,246 participants · Start Nov 30, 2016 · Primary completion Nov 8, 2019
Drug: Ribociclib; Letrozole and 2 more · For: Breast Cancer
Sites: Anchorage, Alaska; Chandler, Arizona; Phoenix, Arizona · 495 sites in all
- Aspirin in Preventing Recurrence of Cancer in Patients With HER2 Negative Stage II-III Breast Cancer After Chemotherapy, Surgery, and/or Radiation TherapyPivotal-lookingTerminated
Alliance for Clinical Trials in OncologyAcademic, hospital or other
NCT02927249 · 3,021 participants · Start Jan 6, 2017 · Primary completion Dec 13, 2021
Drug: Aspirin · For: Node Positive HER2 Negative Breast Cancer
Sites: Birmingham, Alabama; Daphne, Alabama; Mobile, Alabama · 1,452 sites in all
- Efavirenz or Atazanavir/Ritonavir Given With Emtricitabine/Tenofovir Disoproxil Fumarate or Abacavir/Lamivudine in HIV Infected Treatment-Naive AdultsPivotal-lookingCompleted
Advancing Clinical Therapeutics Globally for HIV/AIDS and Other InfectionsResearch network
NCT00118898 · 1,864 participants · Start Sep 2005 · Primary completion Nov 2009
Drug: Abacavir/Lamivudine; Atazanavir and 5 more · For: HIV Infections
Sites: Los Angeles, California; Palo Alto, California; San Diego, California · 52 sites in all
- Clinical Utility Of Genetic Screening For HLA-B*5701, On Susceptibility To Abacavir HypersensitivityPivotal-lookingCompleted
GlaxoSmithKlineGSK (GSK)
NCT00340080 · 1,806 participants · Start Apr 2006
Drug: Abacavir · For: HIV Infection
Sites: Darlinghurst, Australia; Miami, Australia; Graz, Austria · 254 sites in all
- A Study to Evaluate the Long-Term Effectiveness of Three Anti-HIV Drug Regimens in HIV Infected Patients Who Have Never Been Exposed to Highly Active Antiretroviral Therapy (HAART)Pivotal-lookingCompleted
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00000922 · 1,710 participants · Primary completion Jan 2003
Drug: Indinavir sulfate; Abacavir sulfate and 6 more · For: HIV Infections
Sites: San Francisco, California; Denver, Colorado; New Haven, Connecticut · 17 sites in all
National Institute of Allergy and Infectious Diseases (NIAID)NIH
NCT00042289 · 1,578 participants · Start Jun 9, 2003 · Primary completion Sep 30, 2020
Drug: atazanavir/cobicistat; darunavir/ritonavir dosage #1 and 55 more · For: HIV Infections
Sites: Birmingham, Alabama; La Jolla, California; Long Beach, California · 62 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Algorand-proof-of-stake blockchain based-digitalized healthcare data security using protected smart contract and behavioural analyzation.
Bala Gayathri D, Sangeetha D · Comput Biol Chem 2027
- In silico screening of phytochemical inhibitors against Agrobacterium proteins using ADMET prediction, molecular docking, molecular dynamics simulation, and in vitro antimicrobial evaluation.
Attar S, Phatake Y, Marathe R · Comput Biol Chem 2027
- Efflux pump gene ABCA as targets for deep learning-based de novo inhibitors in invasive aspergillosis caused by Aspergillus fumigatus.
Ahmed NM, Ismail RSN, Suleiman AA · Comput Biol Chem 2027
- Production of protocatechuic acid from terephthalic acid by engineered Shewanella oneidensis MR1 and its application to azo dye reduction with bioelectrochemical systems.
Kim S, Doh G, Kim TY, et al. · Bioelectrochemistry 2027
- Polyphosphorylcholine-modified liposomes for glioblastoma-targeted siRNA delivery across the blood-brain barrier.
Ismail M, Wang N, Li Y, et al. · Biomaterials 2027
- First report of PLSA resistance gene sal(B) in multidrug-resistant foodborne Mammaliicoccus lentus: Molecular characterization and food safety implications.
Zhang F, Ma S, Gao J, et al. · Int J Food Microbiol 2027
Also in development for HIV Infections
- rHuPH20Phase 35 trials
Bristol Myers Squibb · Melanoma, Relapsing-remitting Multiple Sclerosis, Clear Cell Renal Cell Carcinoma
- TeropavimabTAB, GS-5423Phase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- ZinlirvimabGS-2872, ZABPhase 33 trials
Gilead Sciences · HIV-1 Infection, HIV Infections, HIV-1-infection
- 2 NRTIsPhase 32 trials
Merck & Co. · Human Immunodeficiency Virus (HIV) Infection, Infection, Human Immunodeficiency Virus, HIV Infections
- ARTPhase 32 trials
GSK · HIV Infections, HIV-1 Infection
- DTGPhase 32 trials
Jiangsu Aidea Pharmaceutical Group Co., Ltd. · Infection, Human Immunodeficiency Virus, HIV Infections
- BMS-663068Phase 31 trial
GSK · HIV Infections
- JL18008Phase 21 trial
Jecho Biopharmaceuticals Co., Ltd. · HIV Infections
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from GSK.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.